Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Harvest Biotech Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area. The company's patent prosecution profile currently features 1 pending office action. This 1 pending office action indicates a highly concentrated prosecution effort for the company's current filings at the USPTO.
The prosecution activity is situated within 1 distinct examiner and 1 distinct art unit. The busiest examiner for the portfolio is HIBBERT, CATHERINE S, who is currently managing 1 pending office action. This concentration within 1 distinct art unit suggests that the technical scope of the pending matter is focused within a specific area of Biotechnology & Pharmaceuticals.
For practitioners, having 1 distinct examiner and 1 pending office action means that the prosecution strategy is entirely focused on a single set of examiner requirements. The role of HIBBERT, CATHERINE S is central to the company's current USPTO engagement. This focused approach allows for a more efficient response to the 1 pending office action without the need to manage varying examiner styles across the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIBBERT, CATHERINE S | 1 | 58.9% | +48.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557911 | ASCORBIC ACID POLYPEPTIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HIBBERT, CATHERINE S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557911 | ASCORBIC ACID POLYPEPTIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HIBBERT, CATHERINE S | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18557911 | ASCORBIC ACID POLYPEPTIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HIBBERT, CATHERINE S | 1658 | §102§103 | Non-Final OA | — | Pending | Oct 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial